← Leaderboards
A. Dimitrios Colevas
Stanford University
$5,652,313
Attributed
$13,484,306
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.2M · FY2019–25$10M$7.5M$5M$2.5M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,484,306 · 2
By mechanism
UM1$10,442,658 · 1
R01$3,041,648 · 1
Top collaborators
- Primo N Lara4 shared
- Heinz Josef Lenz4 shared
- Alexey V. Danilov2 shared
- Miguel Angel Villalona2 shared
Most similar at Stanford University
Same institution · by research overlap
- Olivia M Martinez$20,491,021
- Neda Sattarnezhad Oskouei$385,992
- Quynh-Thu X Le$15,492,013
Others in their field
Other Emerging Leaders on “Tumor”
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,794,323
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$105,180,681
- Leonard Freedmand · Leidos Biomedical Research, Inc.$78,762,245
- Connie Suders · Leidos Biomedical Research, Inc.$67,882,919
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
TumorPharmaceutical PreparationsDrug KineticsNovel TherapeuticsToxic EffectSafetyClinical TrialsDoseInfrastructureMalignant NeoplasmsPharmacodynamicsPre-ClinicalBiological MarkersResearch PersonnelBiopsyAftercareComprehensive Cancer CenterDesignFundingCancer TherapyLaboratoriesLeadPharmacologyMeetings
Grant awards (9)
Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN$1,903,401
UM1 · FY2025 · CA
Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN$1,293,587
UM1 · FY2024 · CA
Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN$1,594,203
UM1 · FY2023 · CA
Phase one clinical trial of a novel small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein- Barr positive nasopharyngeal cancer, with pharmacokinetic and pharmacodynamic correlative studies$582,474
R01 · FY2023 · CA · contact PI
Phase one clinical trial of a novel small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein- Barr positive nasopharyngeal cancer, with pharmacokinetic and pharmacodynamic correlative studies$611,419
R01 · FY2022 · CA · contact PI
Phase one clinical trial of a novel small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein- Barr positive nasopharyngeal cancer, with pharmacokinetic and pharmacodynamic correlative studies$623,900
R01 · FY2021 · CA · contact PI
Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN$5,651,467
UM1 · FY2020 · CA
Phase one clinical trial of a novel small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein- Barr positive nasopharyngeal cancer, with pharmacokinetic and pharmacodynamic correlative studies$594,362
R01 · FY2020 · CA · contact PI
Phase one clinical trial of a novel small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein- Barr positive nasopharyngeal cancer, with pharmacokinetic and pharmacodynamic correlative studies$629,493
R01 · FY2019 · CA · contact PI